contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


prostatype-genomics-publishes-its-interim-report-for-the-first-half-of-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Prostatype Genomics operates in the medical technology sector. The company specializes in the development of medical genetic tests used for the identification, analysis and further follow-up of prostate cancer. In addition to its main business, related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic market. The head office is located in Nacka Strand.

Prostatype Genomics

Prostatype Genomics AB today publishes its interim report for the first half of 2025. The full interim report is attached and can also be downloaded from the company’s website, www.prostatypegenomics...

<div class="mfn-preamble">Prostatype Genomics AB today publishes its interim report for the first half of 2025. The full interim report is attached and can also be downloaded from the company’s website, www.prostatypegenomics.com.</div><div class="mfn-body">First half of 2025,1 January – 30 June 2025<ul><li>Net sales amounted to 246 TSEK (115)</li><li>EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -18,971 TSEK (-18,437)</li><li>Cash flow from operating activities amounted to -17,079 TSEK (-23,211)</li><li>Total cash flow for the period amounted to 3,517 TSEK (-935)</li><li>Earnings per share* amounted to -0.65 SEK (-19.85)</li></ul>* Values for historic earnings per share have been recalculated to reflect the reversed share split 1000:1 which was carried out during the second half of 2024.CEO Fredrik Rickman comments: "In the first half of 2025, we were able to announce that over 10 well-respected American urologists have now started using Prostatype® clinically. Furthermore, both positive preliminary results from the U.S. study with leading institutions and strong published results from a study in Taiwan were presented. Most gratifying, however, is that we expect an approval of our Medicare application this autumn after an active dialogue in a positive spirit with Medicare during the period.”For more information, please contact: Fredrik Rickman, CEO Prostatype Genomics AB Telephone: +46 (0)73 049 77 01 Email: <a rel="noopener" href="mailto:fredrik.rickman@prostatypegenomics.com">fredrik.rickman@prostatypegenomics.com</a>Certified Adviser DNB Carnegie Investment Bank AB Telephone: +46 (0)73 856 42 65 E-mail: <a rel="noopener" href="mailto:certifiedadviser@carnegie.se">certifiedadviser@carnegie.se</a>About Prostatype Genomics AB Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institute and is provided by Prostatype Genomics AB.</div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar">This information is information that Prostatype Genomics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-07-23 12:10 CEST.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments <a rel="noopener" href="https://storage.mfn.se/68574812-1eec-4997-a8c2-03612883f51c/prostatype-2025-h1-eng.pdf" class="mfn-primary">Prostatype 2025 H1 ENG</a></div>